
Photo of Stephen Liu from X
Apr 13, 2024, 12:35
Stephen V Liu: Some guidance on the management of adverse events with sotorasib in KRAS G12C NSCLC Lung Cancer Journal
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University, shared a post on X:
“Some guidance on the management of adverse events with sotorasib in KRAS G12C NSCLC Lung Cancer Journal. Most common grade 2+ adverse events were diarrhea and hepatotoxicity, esp if given after immunotherapy. Close monitoring and dose modification important.”
Read further.
Source: Stephen V Liu/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 13:28
Feb 22, 2025, 13:10
Feb 22, 2025, 13:04
Feb 22, 2025, 11:28
Feb 22, 2025, 11:22
Feb 22, 2025, 11:15
Feb 22, 2025, 11:02
Feb 22, 2025, 10:47